limula

Unlocking Cell Therapy manufacturing at the Point of Care



Luc Henry, CEO
27 June 2025

luc.henry@limula.ch
+41 766 93 23 00

A NEW ERA IN MEDICINE

‘Living drugs’ cure cancer



The New York Times

In Girl’s Last Hope, Altered Immune Cells Beat Leukemia

Low Market Penetration

<5%

of the 500,000 eligible patients for on-market cell therapies received a dose in 2024*.



limula

Image credit: New York Times and Emily Whitehead Foundation; *corresponding to 10,000 patients treated.
Source: Ori Biotech Patient Tracker https://oribiotech.com/insight/patient-access-tracker

OUR STARTING POINT

New tools for new medicines



One patient = one batch



Closed and automated

OUR VISION

From 10’000 to 1’000’000

#1 Intensification



10x

More patients treated

#2 Decentralisation



100x

More patients treated

Point of care requires integrated systems

MODULAR



Semi-automated

- Large footprint, with need to integrate devices in modular way, dealing with different vendors.
- Labour-intensive, with manual tubing connection and cell transfer between devices.

cytiva TERUMO WILSONWOLF MaxCyte SARTORIUS CellFE FRESENIUS KABI Oribiotech

ROBOTIC



Modules into platforms

- Manual handling replaced by robotic arm, reducing manual interventions.
- Large footprint, high initial adoption costs and complex digital interconnectivity step.

MultiplyLabs

cellularorigins A TTP Company

INTEGRATED



End-to-end systems

- Fully automated and end-to-end, removing the majority of human intervention.
- Ease of adoption, lower costs and potential for high throughput and decentralisation.

Lonza Miltenyi Biotec CELLQUEST ATMP MODULAR SYSTEMS ASTRAVEUS mfx CELLARES

OUR SOLUTION

Streamlined production in a single device



CLOSED

Sequencing all steps in a single closed device reduces the risk of contamination

LOWER FACILITY COSTS

AUTOMATED

We take away the human factor, and the associated risk of errors in manipulations.

LOWER LABOUR COSTS

COMPACT

Our table-top solution replaces multiple devices with a lower GMP facility footprint.

LOWER CONSUMABLE COSTS

OUR INTELLECTUAL PROPERTY

Not just a bioreactor.
A totally new way to manipulate cells ex vivo

- **Patent granted worldwide**
- **IP is sole property of Limula SA**

  For more details: WO/2019/234033

  New submission: PCT/EP2023/087909



Novel Design
Unique shape gives functionalities

2-Axis Rotation
Tilt from vertical to horizontal

In-situ Centrifugation
Up to 400g (2500rpm)

Cell expansion. Best in class, across scales





OUR RESULTS SHOW

- Over 250-fold T cell expansion in 10 days, 3-fold superior to control
- Improved lentiviral transduction leads to T cell product expressing CAR construct
- Fully scalable, with automated volume management from 2 mL to 500 mL

OUR OFFERING

Cell processing. Fully automated, on demand



OUR RESULTS SHOW

- Low shear centrifugation = high cell viability
- Low dead volume = high cell recovery rate
- Low hands-on time, short processing time

OUR PRODUCT

LimONE

The new standard in cell therapy manufacturing

EFFICIENT

Solution combining a bioreactor and a centrifuge into one, for the first time – compact, closed and automated system, designed with end-to-end cell therapy processes in mind.

INTUITIVE

Ease of operation leads to effortless, cost-effective adoption by end users. Low training requirements and seamless process transfer and scalability.

VERSATILE

Supporting multiple cell therapy modalities – our innovation delivers functionalities and performance superior to competing technologies.



PRODUCT STATUS

LimGROW product on sale

PRODUCT STATUS

LimONE

Prototype in use by early adopters

OUR VALUE PROPOSITION

One platform – from R&D to GMP

Discovery | Preclinical | Clinical Trials | Commercial

LimGROW



LimONE





Scale down

Lower reagent use leading to up to **90%** reduction in process development costs.

Scale up

Seamless transfer to automation saving up to **6 months** in development time.

Scale out

Fast roll out of manufacturing to multiple sites leading to **early peak sales.**

No more technology transfer

Seamless transition from manual to fully-automated using identical process parameters

- **From 100 million to 4 billion T cells** in 8 days (40-fold expansion)
- **Same cell growth curve**



OUR TRACTION

Pilots completed in 2024

CAR T

HSC

TCR T

NK

What Experts Say

"The solution Limula is advancing is improving the status quo in Cell & Gene Therapy manufacturing, by minimizing cell loss across a broad range of scales, **something not available from existing cell processing solutions**."

Prof. Luigi Naldini
Director, San Raffaele
Institute for Gene Therapy

Prof. Bernhard Gentner
Oncology Department
CHUV

OUR TEAM

Combining deep expertise in Cell and Gene Therapy with ‘Swiss Made’ precision engineering

Lausanne, Switzerland

20
People

11
Nationalities

OUR JOURNEY

Join our Series A, support our commercial success!



limula

Reach out to learn more!

luc.henry@limula.ch

Luc Henry, CEO
27 June 2025

Limula SA
Rte de la Corniche 5, CH-1066 Epalinges

THEY BELIEVE IN LIMULA